DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,080,371 B2 Ballinger Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,080,371 B2 Ballinger Et Al USO08080371B2 (12) United States Patent (10) Patent No.: US 8,080,371 B2 Ballinger et al. (45) Date of Patent: Dec. 20, 2011 (54) MARKERS FOR ADDICTION FOREIGN PATENT DOCUMENTS WO WO92fO2638 * 2/1992 (75) Inventors: Dennis Ballinger, Menlo Park, CA (US); Karel Konvicka, San Francisco, OTHER PUBLICATIONS CA (US); Laura Jean Bierut, St. Louis, MO (US); John Rice, St. Louis, MO Langdahl, Bente et al. Osteoporotic fractures are assoicated with an (US); Frank Scott Saccone, St. Louis, 86 base pair repeat polymoprhism in the interleukin 1 receptor MO (US); Anthony L. Hinrichs, St. antagonist gene but not with polymoprhisms in the interleukin 1B Louis, MO (US); Alison M. Goate, St. gene. 2000. Journal of Bone and Mineral Research. vol. 15 No. 3 pp. Louis, MO (US); Jen Wang, Ballwin, 402-414. MO (US) Wall, Jeffery et al. Haplotype blocks and linkage disequilbirium in the human genome. 2003. Nature Reviews Genetics. vol. 4 pp. 587 (73) Assignee: The Washington University, St. Louis, 597.* MO (US) Arnhelm, N., et al., C&EN 36-47 (1990).* Barrett J.C., et al., Bioinformatics 21(2):263-265 (2005).* (*) Notice: Subject to any disclaimer, the term of this Barringer, K.J., et al., Gene 89:117-122 (1990).* patent is extended or adjusted under 35 Beaucage, S.L., et al., Tetrahedron Letts.–22(20): 1859-1862 U.S.C. 154(b) by 18 days. (1981).* Becker, J., et al., Mol Gen Genet 249:65-73 (1995).* (21) Appl. No.: 11/681,177 Benjamini, Y., et al., J.R. Stat. Soc. B–57(1):289-300 (1995). Beuten, J., et al., Am. J. Hum. Genet. 76:859-864 (2005). (22) Filed: Mar. 1, 2007 Beuten, J., et al., Am. J. Med. Genet. B Neuropsychiatr. Genet.— 139:73-80 (2005). (65) Prior Publication Data Bierut, L.J. et al., Hum. Mot. Genet.—16(1):24-35 (2007). US 2007/O258898A1 Nov. 8, 2007 Bierut, L.J., et al., Am. J. Med. Genet.—124A:19-27 (2004). Bierut, L.J., et al., Arch. Gen. Psychiatry -55:982–988 (1998). Related U.S. Application Data Blok, H.J., et al., Mol Cell Probes–11:187-194 (1997). Bonnet, G., et al., Proc. Natl. Acad. Sci. U.S.A.–96:6171-6176 (60) Provisional application No. 60/778,597, filed on Mar. (1999). 1, 2006, provisional application No. 60/811,318, filed Boustead. C. et al., Pharmacogenetics—7:411-414 (1997). on Jun. 6, 2006. Breslau, N., et al., Psychol. Med. 34:323-333 (2004). Breslau, N., et al., Biol. Psychiatry–55:69-76 (2004). (51) Int. Cl. Breslau, N., et al., Am. J. Public Health 90:1122-1127 (2000). CI2O I/68 (2006.01) Busby, V., et al., Neuromolecular Med—5:133-146 (2004). CI2P 19/34 (2006.01) Butt, C.M., et al. Alcohol. Clin. Exp. Res. 27(5):733-742 (2003). C7H 2L/04 (2006.01) Butt, C.M., et al., Behav Neurosci-119(1):26-37 (2005). (52) U.S. Cl. ........ 435/6; 435/91.2:536/24.33: 536/23.1 CDC (2005) Annual smoking-attributable mortality, years of poten (58) Field of Classification Search ........................ None tial life lost, and productivity losses United States, 1997-2001— See application file for complete search history. Morbidity & Mortality Weekly Report 54.625-628. CDC (2005) Cigarette Smoking among adults United States, (56) References Cited 2004 Morbidity & Mortality Weekly Report–54:121-1124. CDC (2004) Cigarette use among high school students United U.S. PATENT DOCUMENTS States, 1991-2003 Morbidity & Mortality Weekly Report 53:499 4,683.202 A * 7/1987 Mullis 5O2. 5,045,694. A * 9, 1991 Beavis et al. Carlson, C.S., et al., Am. J. Hum. Genet. 74: 106-120 (2004). 5,202,561 A * 4, 1993 Giessmann et al. 5,468,613 A * 1 1/1995 Erlich et al. (Continued) 5,925,517 A * 7/1999 Tyagi et al. 6,037,130 A * 3/2000 Tyagi et al. 6,111.251 A * 8/2000 Hillenkamp Primary Examiner — Amanda Shaw 6,150,097 A * 1 1/2000 Tyagi et al. 6,174,670 B1* 1/2001 Wittwer et al. 6,342,355 B1* 1/2002 Hacia et al. 6,740,510 B2 * 5, 2004 Kautzer et al. (57) ABSTRACT 6,897,025 B2* 5/2005 Cox et al. 6,898,531 B2* 5/2005 Sheehan et al. Correlations between polymorphisms and addiction are pro 6,969,589 B2 * 1 1/2005 Patilet al. vided. Methods of diagnosing, prognosing, and treating 7,127,355 B2 * 10/2006 Cox et al. 2003. O108919 A1* 6, 2003 Kautzer et al. addiction are provided. Systems and kits for diagnosis, prog 2004/OO23237 A1* 2, 2004 Patil et al. nosis and treatment of addiction are provided. Methods of 2004/0229224 A1* 11, 2004 Frazer et al. identifying addiction modulators are also described. 2004/0241657 A1* 12, 2004 Patil et al. 2005.0003410 A1* 1/2005 Frazer et al. 2005/OOO7375 A1* 1/2005 Y 2005, OO19787 A1* 1/2005 Berno et al. 6 Claims, 27 Drawing Sheets 2006,0166224 A1* 7, 2006 Norvel (10 of 27 Drawing Sheet(s) Filed in Color) US 8,080,371 B2 Page 2 OTHER PUBLICATIONS Liu, Q.R. et al., Proc. Natl. Acad. Sci. U. S. A.—102: 11864-11869 (2005). Carmelli, D., et al., N. Engl. J. Med. 327(12):829-833 (1992) Lockhart, D.J., Nature Medicine 4:1235-1236 (1998). Abstract Only. Lomell, H., et al., J. Clin. Chem.–35:1826-1831 (1989). Chee, M., et al., Science 274:610-614 (1996). Lowry, O. H., et al. J. Biol. Chem.–193:265-275 (1951). Cheng, S., et al., Nature 369:684-685 (1994). Ma, J.Z., et al., Hum. Mol. Genet.–14(12): 1691-1698 (2005). Cholerton, S., et al., Pharmacogenetics—6:261-263 (1996). Madden, P.A., et al., Behav. Genet. 29(6):423-431 (1999). Comings, D.E., et al., Pharmacogenetics—6:73-79(1996). Marks, M. J., et al., J. Pharmacol. Exp. Ther. 285(1):377-386 Corrigall, W.A., et al., Brain. Res. 653:278-284 (1994). (1998). Craig, A.M., et al., Trends Neurosci...—29:8-20 (2006). Marras, S.A.E., et al., Genet. Anal. Biomol. Eng.—14:151-156 Cserzo, M., et al., Protein Eng–10(6):673-676 (1997). (1999). Dobelis, P., et al., Mol. Pharmacol.–62(2):334-342 (2002). Meksem, K., et al., Mol. Gen. Genet.—249:74-81 (1995). Dobson-Stone, C., et al., Eur: J. Hum. Genet.—10:773-781 (2002). Merikangas, K.R., et al., Arch Gen Psychiatryi–55:973-979 (1998). Ertekin-Taner, N., et al., Hum. Mol. Genet.—12,3133-3143 (2003). Needham-VanDevanter, D.R., et al., Nucleic Acids Res.— Fang, X. et al. J. Am. Chem. Soc.–121:2921-2922 (1999). 12(15):6159-6168 (1984). Feng, Y, et al., Am. J. Hum. Genet. 75: 112-121 (2004). Pianezza, M.L., et al. Sellers.E.M., and Tyndale, RF. Nicotine Zeng, Z. et al., Cell 127:621-633 (2006). metabolism defect reduces Smoking. Nature 393:750 (1998). Fodor, P.A., FASEB Journal 11:A879 (1997). Pritchard, J.K., et al., Genetics Society of America —155:945-959 Fodor, S.P.A. Science 277:393-395 (1997). (2000). Gelernter, J. et al., Am. J. Med. Genet. B Neuropsychiatr. Genet.— Roeder, K., et al., Am. J. Hum. Genet. 78,243-252 (2006). 128B:94-101 (2004). Saccone, S.F., et al., Genet. Epidemiol.—30:459-470 (2006). Grant, B.F., et al., Arch. Gen. Psychiatry—61:1107-1115 (2004). Saccone, S.F., et al., Hum. Mol. Genet.—16(1):36-49 (2006). Greenbaum, L., et al., Mol. Psychiatr.—11:312-322 (2006). Salminen, O., et al., Mol. Pharmacol.–65(6):1526-1535 (2004). Guatelli, J.C., et al., Proc. Natl. Acad. Sci. USA-87: 1874-1878 Sapolsky, R.J., et al., Genetic Analysis. Biomolecular Engineering— (1990). 14:187-192 (1999). Heath, A.C., et al., Addict. Behav.–18:19-34 (1993). Satagopan, J.M., et al., Biometrics—58:163-170 (2002). Heatherton, T.F., et al., Br. J. Addict.–86: 1119-1127 (1991). (Service (1998) Science 282:396–401(1998). Heatherton, T.F., et al., Br. J. Addict.–84:791-800 (1989). Shields, P.G., et al., Cancer Epidemiol. Biomarkers Prev. 7:453 Hegab, A.E., et al., J. Med. Genet.—41:(e27):1-7 (2004). 458 (1998). Hinds, D.A., et al., Science 307: 1072-1079 (2005). Skol, A.D., et al., Nat. Genet. 38(2):209-213 (2006). Hinds, D.A., et al., Am. J. Hum. Genet.—74:317-325 (2004). Sooknanan, R., et al., Biotechnology—13:563-564 (1995). Hochberg, Y, et al., Stat. Med. 9:811-818 (1990). Sokol, D.L., et al., Proc. Natl. Acad. Sci. U.S.A. 95:11538-11543 Hsuih, T.C.H., et al., J. Clin. Microbiol. 34(3):501-507 (1996). (1998). Hu, S., et al., Mol. Psychiatry 5:181-188 (2000). Spitz, M.R. et al., J. Natl. Cancer. Inst. 90(5):358-363 (1998). Iacono, W.G., et al., Arch. Gen. Psychiatry: 59.750-757 (2002). Stein, L.D., et al., Genome. Res.–12:1599-1610 (2002). Issaq, H.J., et al., (Analytical Chemistry: 75:149A-155A (2003). Stitzel, J.A., et al., Pharmacogenetics—11:331-339 (2001). Jeulin, C., et al., Am. J. Physiol. Lung Cell. Mol. Physiol.— Storey, J.D., J. R. Statist. Soc. B–64:479–498 (2002). 289:L636-L646 (2005). Storey, J.D., et al., Proc. Natl. Acad. Sci-100(16):9440-9445 Karadsheh, M. S., et al., J. Neurochem.—91: 1138-1150 (2004). (2003). Kostrikis, L.G., et al., Science 279:1228-1229 (1998).
Load more

Recommended publications
  • Supplementary Data
    Supplementary Methods Mutation and microdeletion screening by high resolution melting High-throughput mutation screening of DIS3L2 exons 1-16 and HDAC4 was performed by Lightscanner high resolution melting analysis (Idaho Technology, Salt Lake City, UT). Exons 17-21 of DIS3L2 were not sequenced due to an apparent genomic duplication and consequent inability to uniquely amplify these exons. DNA samples were amplified using LightScanner mastermix under the manufacturer’s guidelines (Idaho Technology). After PCR, samples were heated at 0.1°C/s in the Lightscanner instrument and fluorescence was collected from 60 to 95°C. Melting curves were analyzed using LightScanner software (v2.0, Idaho Technology). Microdeletion screening across DIS3L2 was performed on paired normal- tumor samples using Lightscanner Lunaprobe SNP genotyping. Seven SNPs, ~60 Kb apart (rs2679184, rs12988522, rs4973500, rs3100586, rs3116179, rs923333 and rs2633254) were amplified in separate reactions and analyzed as above. Detailed conditions and primer/probe sequences are available on request. Variant amplicons were sequenced as described below. Direct sequencing was also performed for all exons where a common polymorphism might mask detection of a mutation by Lightscanner. Samples with known LOH were analyzed entirely by direct sequencing, since Lightscanner detects altered melting profiles of DNA heteroduplexes and these cannot exist in hemizygous samples. Sequencing of candidate genes Direct sequencing of exons and flanking consensus splice signals was performed for DIS3L2, GIGYF2, NPPC, HDAC4, TWIST2 and miR-562. PCR amplification was performed using HotStarTaq Mastermix and Q solution (Qiagen, Valencia, CA); all conditions and primers are available on request. PCR products were treated with shrimp alkaline phosphatase and exonuclease-I (New England Biolabs, Ipswich, MA) and sequenced using BigDye terminator chemistry on a 3730xl sequencer (Applied Biosystems, Foster City, CA).
    [Show full text]
  • Research Article Microarray-Based Comparisons of Ion Channel Expression Patterns: Human Keratinocytes to Reprogrammed Hipscs To
    Hindawi Publishing Corporation Stem Cells International Volume 2013, Article ID 784629, 25 pages http://dx.doi.org/10.1155/2013/784629 Research Article Microarray-Based Comparisons of Ion Channel Expression Patterns: Human Keratinocytes to Reprogrammed hiPSCs to Differentiated Neuronal and Cardiac Progeny Leonhard Linta,1 Marianne Stockmann,1 Qiong Lin,2 André Lechel,3 Christian Proepper,1 Tobias M. Boeckers,1 Alexander Kleger,3 and Stefan Liebau1 1 InstituteforAnatomyCellBiology,UlmUniversity,Albert-EinsteinAllee11,89081Ulm,Germany 2 Institute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen, Pauwelstrasse 30, 52074 Aachen, Germany 3 Department of Internal Medicine I, Ulm University, Albert-Einstein Allee 11, 89081 Ulm, Germany Correspondence should be addressed to Alexander Kleger; [email protected] and Stefan Liebau; [email protected] Received 31 January 2013; Accepted 6 March 2013 Academic Editor: Michael Levin Copyright © 2013 Leonhard Linta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ion channels are involved in a large variety of cellular processes including stem cell differentiation. Numerous families of ion channels are present in the organism which can be distinguished by means of, for example, ion selectivity, gating mechanism, composition, or cell biological function. To characterize the distinct expression of this group of ion channels we have compared the mRNA expression levels of ion channel genes between human keratinocyte-derived induced pluripotent stem cells (hiPSCs) and their somatic cell source, keratinocytes from plucked human hair. This comparison revealed that 26% of the analyzed probes showed an upregulation of ion channels in hiPSCs while just 6% were downregulated.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Replicated Risk Nicotinic Cholinergic Receptor Genes for Nicotine Dependence
    G C A T T A C G G C A T genes Article Replicated Risk Nicotinic Cholinergic Receptor Genes for Nicotine Dependence Lingjun Zuo 1, Rolando Garcia-Milian 2, Xiaoyun Guo 1,3,4,*, Chunlong Zhong 5,*, Yunlong Tan 6, Zhiren Wang 6, Jijun Wang 3, Xiaoping Wang 7, Longli Kang 8, Lu Lu 9,10, Xiangning Chen 11,12, Chiang-Shan R. Li 1 and Xingguang Luo 1,6,* 1 Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA; [email protected] (L.Z.); [email protected] (C.-S.R.L.) 2 Curriculum & Research Support Department, Cushing/Whitney Medical Library, Yale University School of Medicine, New Haven, CT 06510, USA; [email protected] 3 Shanghai Mental Health Center, Shanghai 200030, China; [email protected] 4 Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06510, USA 5 Department of Neurosurgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China 6 Biological Psychiatry Research Center, Beijing Huilongguan Hospital, Beijing 100096, China; [email protected] (Y.T.); [email protected] (Z.W.) 7 Department of Neurology, Shanghai First People’s Hospital, Shanghai Jiao Tong University, Shanghai 200080, China; [email protected] 8 Key Laboratory for Molecular Genetic Mechanisms and Intervention Research on High Altitude Diseases of Tibet Autonomous Region, Xizang Minzu University School of Medicine, Xianyang, Shanxi 712082, China; [email protected] 9 Provincial Key Laboratory for Inflammation and Molecular Drug Target, Medical
    [Show full text]
  • Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression Is Associated with Response to Varenicline Treatment
    Profile of the nicotinic cholinergic receptor alpha 7 subunit gene expression is associated with response to varenicline treatment Juliana Rocha Santos1, Paulo Roberto Xavier Tomaz1, Jaqueline Scholz2, Patrícia Viviane Gaya2, Tânia Ogawa Abe2, José Eduardo Krieger1, Alexandre Costa Pereira1, Paulo Caleb Júnior Lima Santos3* 1 Laboratory of Genetics and Molecular Cardiology, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. 2 Smoking Cessation Program Department, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. 3 Department of Pharmacology – Escola Paulista de Medicina, Universidade Federal de Sao Paulo, EPM-Unifesp, Sao Paulo, Brazil. Supplementary table 1 - Median values of ∆CT genes according with time periods and outcome groups Resistant T0 Resistant T2 Resistant T4 ∆CT IC 95% ∆CT IC 95% ∆CT IC 95% CHRNA5 8.18 (7.32 – 8.70) 8.45 (7.48 – 8.87) 7.67 (7.27 – 9.05) CHRNA7 6.62 (6.17 – 6.97) 8.02 (7.07 – 8.48) 7.19 (6.96 – 7.86) CHRNG 6.20 (5.79 – 6.95) 6.47 (6.01 – 6.68) 6.63 (6.02 – 7.02) COMT 4.67 (4.40– 5.01) 4.80 (4.43 – 5.03) 4.87 (4.52 – 5.24) Success T0 Success T2 Success T4 ∆CT IC 95% ∆CT IC 95% ∆CT IC 95% CHRNA5 8.32 (7.38 – 9.17) 7.07 (6.53 – 8.96) 8.37 (7.54 – 8.82) CHRNA7 7.26 (6.11 – 8.42) 7.04 (6.40 – 7.79) 7.38 (6.76 – 8.20) CHRNG 6.82 (6.19 – 7.74) 6.83 (6.56 – 7.33) 6.59 (6.25 – 7.03) COMT 4.88 (4.30 – 5.11) 4.58 (4.33 -5.15) 4.81 (4.48 – 5.16) ∆CT = (CT target gene – CThousekeepings genes mean).
    [Show full text]
  • Retrograde Inhibition by a Specific Subset of Interpeduncular Α5 Nicotinic Neurons Regulates Nicotine Preference
    Retrograde inhibition by a specific subset of interpeduncular α5 nicotinic neurons regulates nicotine preference Jessica L. Ablesa,b,c, Andreas Görlicha,1, Beatriz Antolin-Fontesa,2,CuidongWanga, Sylvia M. Lipforda, Michael H. Riada, Jing Rend,e,3,FeiHud,e,4,MinminLuod,e,PaulJ.Kennyc, Nathaniel Heintza,f,5, and Ines Ibañez-Tallona,5 aLaboratory of Molecular Biology, The Rockefeller University, New York, NY 10065; bDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029; cDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029; dNational Institute of Biological Sciences, Beijing 102206, China; eSchool of Life Sciences, Tsinghua University, Beijing 100084, China; and fHoward Hughes Medical Institute, The Rockefeller University, New York, NY 10065 Contributed by Nathaniel Heintz, October 23, 2017 (sent for review October 5, 2017; reviewed by Jean-Pierre Changeux and Lorna W. Role) Repeated exposure to drugs of abuse can produce adaptive changes nicotine withdrawal, and optical activation of IPN GABAergic cells that lead to the establishment of dependence. It has been shown that is sufficient to produce a withdrawal syndrome, while blockade of allelic variation in the α5 nicotinic acetylcholine receptor (nAChR) gene GABAergic cells in the IPN reduced symptoms of withdrawal (17). CHRNA5 is associated with higher risk of tobacco dependence. In the Taken together these studies highlight the critical role of α5in brain, α5-containing nAChRs are expressed at very high levels in the regulating behavioral responses to nicotine. Here we characterize two subpopulations of GABAergic interpeduncular nucleus (IPN). Here we identified two nonoverlapping Amigo1 Epyc α + α Amigo1 α Epyc neurons in the IPN that express α5: α5- and α5- neu- 5 cell populations ( 5- and 5- ) in mouse IPN that respond α Amigo1 α Epyc differentially to nicotine.
    [Show full text]
  • Gene Expression Changes in Glutamate and GABA-A Receptors
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Alcohol Manuscript Author Clin Exp Res. Author Manuscript Author manuscript; available in PMC 2017 May 01. Published in final edited form as: Alcohol Clin Exp Res. 2016 May ; 40(5): 955–968. doi:10.1111/acer.13056. Gene expression changes in glutamate and GABA-A receptors, neuropeptides, ion channels and cholesterol synthesis in the periaqueductal gray following binge-like alcohol drinking by adolescent alcohol-preferring (P) rats Jeanette N. McClinticka,b, William J. McBridec, Richard L. Bellc, Zheng-Ming Dingc, Yunlong Liud, Xiaoling Xueia,b, and Howard J. Edenberga,b,d,* aDepartment of Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, United States bCenter for Medical Genomics, Indiana University School of Medicine, Indianapolis, IN 46202, United States cInstitute of Psychiatric Research, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, United States dDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, United States Abstract Background—Binge-drinking of alcohol during adolescence is a serious public health concern with long-term consequences, including increased pain, fear and anxiety. The periaqueductal gray (PAG) is involved in processing pain, fear and anxiety. The effects of adolescent binge drinking on gene expression in this region have yet to be studied. Methods—Male adolescent P (alcohol preferring) rats were exposed to repeated binge-drinking (three 1-h sessions/day during the dark-cycle, 5 days/week for 3 weeks starting at 28 days of age; ethanol intakes of 2.5 – 3 g/kg/session). We used RNA sequencing to assess the effects of ethanol intake on gene expression.
    [Show full text]
  • Significant Associations of CHRNA2 and CHRNA6 with Nicotine Dependence in European American and African American Populations
    Hum Genet (2014) 133:575–586 DOI 10.1007/s00439-013-1398-9 ORIGINAL INVESTIGATION Significant associations of CHRNA2 and CHRNA6 with nicotine dependence in European American and African American populations Shaolin Wang · Andrew D van der Vaart · Qing Xu · Chamindi Seneviratne · Ovide F. Pomerleau · Cynthia S. Pomerleau · Thomas J. Payne · Jennie Z. Ma · Ming D. Li Received: 20 July 2013 / Accepted: 8 November 2013 / Published online: 20 November 2013 © Springer-Verlag Berlin Heidelberg 2013 Abstract The direct physiological effects that promote both ND measures (with a P value of 0.0043 and 0.00086 nicotine dependence (ND) are mediated by nicotinic ace- for SQ and FTND, respectively) continued to be significant tylcholine receptors (nAChRs). In line with the genetic and in the EA sample even after correction for multiple tests. pharmacological basis of addiction, many previous stud- Further, we found several haplotypes that were significantly ies have revealed significant associations between variants associated with ND in the EA sample in CHRNA6 and in in the nAChR subunit genes and various measures of ND the both EA and AA samples in CHRNA2. To confirm the in different ethnic samples. In this study, we first exam- associations of the two genes with ND, we conducted a ined the association of variants in nAChR subunits α2 replication study with an independent case–control sample (CHRNA2) and α6 (CHRNA6) genes on chromosome 8 from the SAGE study, which showed a significant associa- with ND using a family sample consisting of 1,730 Euro- tion of the two genes with ND, although the significantly pean Americans (EAs) from 495 families and 1,892 Afri- associated SNPs were not always the same in the two sam- can Americans (AAs) from 424 families (defined as the ples.
    [Show full text]
  • Recombinant Human CHRNB3 (C-6His)
    Catalog # CI32 Recombinant Human CHRNB3 (C-6His) Derived from Human Cells Recombinant Human Neuronal Acetylcholine Receptor Subunit Beta-3 is produced by our Mammalian expression system and the target gene encoding Ile25-Leu232 is expressed with a 6His tag at the C- terminus. DESCRIPTION Accession Q05901 Known as Neuronal acetylcholine receptor subunit beta-3 Mol Mass 25.3kDa AP Mol Mass 30-40 kDa, reducing conditions. QUALITY CONTROL Purity Greater than 95% as determined by reducing SDS-PAGE. Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. FORMULATION Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. RECONSTITUTION Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. The product is shipped at ambient temperature. SHIPPING Upon receipt, store it immediately at the temperature listed below. Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. STORAGE Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. Neuronal acetylcholine receptor subunit beta-3(CHRNB3) is a cell membrane protein and belongs to the ligand-gated ion channel (TC 1.A.9) family. CHRNB3 seems to be composed of two different type of subunits: alpha and beta. The CHRNB3 are (hetero) pentamers composed of homologous subunits.
    [Show full text]
  • CHRNA6 Gene Cluster on Chromosome 8 in Nicotine Dependence: Update and Subjects for Future Research
    OPEN Citation: Transl Psychiatry (2016) 6, e843; doi:10.1038/tp.2016.103 www.nature.com/tp REVIEW Crucial roles of the CHRNB3–CHRNA6 gene cluster on chromosome 8 in nicotine dependence: update and subjects for future research LWen1, Z Yang1, W Cui1 and MD Li1,2,3 Cigarette smoking is a leading cause of preventable death throughout the world. Nicotine, the primary addictive compound in tobacco, plays a vital role in the initiation and maintenance of its use. Nicotine exerts its pharmacological roles through nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels consisting of five membrane-spanning subunits. Besides the CHRNA4, CHRNB2 and CHRNA5/A3/B4 cluster on chromosome 15, which has been investigated intensively, recent evidence from both genome-wide association studies and candidate gene-based association studies has revealed the crucial roles of the CHRNB3– CHRNA6 gene cluster on chromosome 8 in nicotine dependence (ND). These studies demonstrate two distinct loci within this region. The first one is tagged by rs13277254, upstream of the CHRNB3 gene, and the other is tagged by rs4952, a coding single nucleotide polymorphism in exon 5 of that gene. Functional studies by genetic manipulation in mice have shown that α6*-nAChRs, located in the ventral tegmental area (VTA), are of great importance in controlling nicotine self-administration. However, when the α6 subunit is selectively re-expressed in the VTA of the α6− / − mouse by a lentiviral vector, the reinforcing property of nicotine is restored. To further determine the role of α6*-nAChRs in the process of nicotine-induced reward and withdrawal, genetic knock-in strains have been examined, which showed that replacement of Leu with Ser in the 9′ residue in the M2 domain of α6 produces nicotine-hypersensitive mice (α6L9′S) with enhanced dopamine release.
    [Show full text]
  • ION CHANNEL RECEPTORS TÁMOP-4.1.2-08/1/A-2009-0011 Ion Channel Receptors
    Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University of Pécs and at the University of Debrecen Identification number: TÁMOP-4.1.2-08/1/A-2009-0011 Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University of Pécs and at the University of Debrecen Identification number: TÁMOP-4.1.2-08/1/A-2009-0011 Tímea Berki and Ferenc Boldizsár Signal transduction ION CHANNEL RECEPTORS TÁMOP-4.1.2-08/1/A-2009-0011 Ion channel receptors 1 Cys-loop receptors: pentameric structure, 4 transmembrane (TM) regions/subunit – Acetylcholin (Ach) Nicotinic R – Na+ channel - – GABAA, GABAC, Glycine – Cl channels (inhibitory role in CNS) 2 Glutamate-activated cationic channels: (excitatory role in CNS), tetrameric stucture, 3 TM regions/subunit – eg. iGlu 3 ATP-gated channels: 3 homologous subunits, 2 TM regions/subunit – eg. P2X purinoreceptor TÁMOP-4.1.2-08/1/A-2009-0011 Cys-loop ion-channel receptors N Pore C C C N N N N C C TM TM TM TM 1 2 3 4 Receptor type GABAA GABAC Glycine g a b p2 p1 b a Subunit diversity a1-6, b1-3, g1-3, d,e,k, and q p1-3 a1-4, b TÁMOP-4.1.2-08/1/A-2009-0011 Vertebrate anionic Cys-loop receptors Type Class Protein name Gene Previous names a1 GABRA1 a2 GABRA2 a3 GABRA3 EJM, ECA4 alpha a4 GABRA4 a5 GABRA5 a6 GABRA6 b1 GABRB1 beta b2 GABRB2 ECA5 b3 GABRB3 g1 GABRG1 GABAA gamma g2 GABRG2 CAE2, ECA2, GEFSP3 g3 GABRG3 delta d GABRD epsilon e GABRE pi p GABRP
    [Show full text]
  • Consequences of NMDA Receptor Deficiency Can Be Rescued in the Adult Brain
    bioRxiv preprint doi: https://doi.org/10.1101/140343; this version posted May 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Consequences of NMDA receptor deficiency can be rescued in the adult brain Catharine A. Mielnik1, Yuxiao Chen1*, Mary A. Binko2*, Rehnuma Islam2, Marija Milenkovic1, Wendy Horsfall1, Ali Salahpour1, Evelyn K. Lambe2, and Amy J. Ramsey1,2 1 Department of Pharmacology & Toxicology, 2 Department of Physiology, University of Toronto, Toronto, ON, M5S 1A8, Canada Amy Ramsey 1 King’s College Circle Room 4302 Medical Sciences Building Toronto, ON M5S 1A8 Canada (416) 978-2509 [email protected] Highlights: GluN1 inducible rescue mice allow recovery of functional NMDA receptors in a neurodevelopmental model of schizophrenia. Rescue in adolescent or adult mice achieves a similar level of functional recovery. Cortically-mediated behaviors show complete or near complete rescue, but subcortically-mediated behaviors show limited rescue. Higher-order brain function appears amenable to treatment in adulthood and surprisingly unencumbered by critical period. 1 bioRxiv preprint doi: https://doi.org/10.1101/140343; this version posted May 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. SUMMARY NMDA receptors (NMDAR) are important in the formation of activity-dependent connections in the brain. In sensory pathways, NMDAR disruption during discrete developmental periods has enduring effects on wiring and function. Yet, it is not clear whether NMDAR-limited critical periods exist for higher-order circuits governing mood and cognition.
    [Show full text]